12:00 AM
 | 
Aug 24, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Panitumumab: Phase III data

Top-line data from a double-blind, placebo-controlled, international Phase III trial (181) in 1,186 patients showed that Vectibix plus FOLFIRI chemotherapy met the co-primary endpoint of significantly improving PFS in patients with wild-type K-Ras vs. FOLFIRI alone. Vectibix plus FOLFIRI missed the co-primary endpoint of significantly improving OS in the same subset of patients vs. FOLFIRI...

Read the full 262 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >